GlassScriptPhysician profile
Kelly Nash
NPI 1982200911
$2,304.84
in general payments reported to CMS, 2019-2025
18 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $382 · 2023: $178 · 2024: $195 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $733.54 | 2021-2025 | Livdelzi, Epclusa |
| Abbvie INC. | $369.22 | 2021-2025 | |
| Redhill Biopharma INC. | $225.76 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.09 | 2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $124.97 | 2022 | |
| Sanofi-Aventis U.S. LLC | $114.33 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.67 | 2022-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $107.13 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $101.06 | 2025 | Dupixent |
| Celltrion USA INC. | $53.64 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $36.38 | 2025 | Tremfya |
| Bayer Healthcare Pharmaceuticals INC. | $35.11 | 2025 | |
| Phathom Pharmaceuticals, INC. | $32.41 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $31.34 | 2022-2025 | Rybelsus, Ozempic |
| Braintree Laboratories, INC. | $25.30 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $16.53 | 2024 | |
| Amgen INC. | $14.73 | 2024 | Repatha, Otezla |
| Lilly USA, LLC | $14.63 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.